
Toward Full Decentralization of Evidence Generation with Medical Devices
Connected medical devices now produce continuous streams of real-world data. For manufacturers, the harder question is how to turn that data into evidence that regulators and payers will accept, without the cost and delays of running clinical sites.
In Europe, hybrid decentralised studies, which combine remote data capture with routine clinic visits, have become the standard approach. They work, but they remain bound by site onboarding, investigator management and slow enrolment. Fully decentralised studies remove the site altogether. In the United States, they have already been used to meet post-market surveillance requirements for automated insulin delivery systems. European regulators remain more cautious, mainly because of how safety data can be independently verified without a site.
This white paper, developed jointly by Arcondis and mylife Diabetes Care, compares the two models, using automated insulin delivery as the reference case. It covers:
- The operational trade-offs. In an illustrative French post-market scenario, a fully decentralised design could halve recruitment time (from 12 to 6 months), enrol 1,000 participants instead of 240 and reduce costs by more than €400,000 (approximately 57%), based on defined study assumptions.
- The regulatory and payer landscape. This includes FDA and EMA guidance, HAS expectations for real-world evidence and France’s confirmation that a participant’s home can qualify as a research site.
- A three-pillar framework for closing the EU gap. The three pillars are direct electronic health record integration, automated safety detection through wearables and linkage with national health databases.
- The emerging role of AI. This ranges from data curation and predictive modelling to agentic AI and adaptive, continuously validated study designs.
The paper concludes that hybrid models remain the most viable route to regulatory-grade evidence in Europe today. It also argues that manufacturers who invest early in interoperable data ecosystems and robust digital quality frameworks will be better prepared for future reimbursement and post-market requirements.
Who should read it: leaders in medical affairs, clinical and regulatory affairs, market access and evidence generation at medtech and digital health companies.
About the Authors
Tim Ting-Yi Lin
Service Owner Medical Product Excellence
![]()
Giovanni Brusaferri
Medical Affairs,
mylife Diabetes Care AG,
Burgdorf, Switzerland
Sandra Rosser
Medical Affairs,
mylife Diabetes Care AG,
Burgdorf, Switzerland